Rheumatoid Arthritis – Drug Pipeline Analysis and Market Forecasts to 2015
12/22/2009

Current Marketed Products are Moderately Successful in Meeting the Patients’ Expectations

Online PR News – 22-December-2009 – – With 13 branded products, current competition in RA market is quite strong. The products currently available in the market have disease modifying properties and show slowing down or even reversal of joint damage. However, the existing marketed products do not have a high safety profile and this creates a market potential for new entrants who can come up with products of improved efficacy and a better safety profile. Currently, the Rheumatoid arthritis therapeutic landscape needs products which can offer a high safety profile with disease modifying properties, faster onset of action and sustained effect spread over a longer time period.

For further details on this report, please or add the below link to your browser
http://www.global-market-research-data.com/CategorySearchResult.aspx?IndustryReport=rheumatoid_arthritis&CoreIndustry=All

The global Rheumatoid arthritis therapeutics market was valued at $16.8 billion in 2008 and will be driven by the increasing ageing population and the steady increase in incidence rates of autoimmune disorders. This market is expected to grow to $26.7 billion with a CAGR of 6.8% by year 2015. The market is increasingly becoming more competitive with introduction of novel therapeutics. Currently there are 13 branded products which include three recently approved ones. Recent launches of Cimzia, Simponi and Lodotra may boost the Rheumatoid arthritis market significantly.

For further details on this report, please or add the below link to your browser
http://www.global-market-research-data.com/CategorySearchResult.aspx?IndustryReport=rheumatoid_arthritis&CoreIndustry=All

Bulk of the Rheumatoid arthritis portfolio is maintained by major market players. Among the companies participating in the Rheumatoid arthritis market, Pfizer, Roche, Biogen, Amgen and Mitsubishi Tanabe are the key players.
Pfizer has one phase III and five Phase I molecules, Roche has two molecules in both Phase III and regulatory filing stage, Biogen has one molecule in both Phase III and regulatory filing stage, Amgen has 2 molecules in Phase II. Mitsubishi Tanabe has one Phase II molecule and two Phase I molecules.

GlobalData, the industry analysis specialist, has released a new report, “Rheumatoid Arthritis – Drug Pipeline Analysis and Market Forecasts to 2015”. The report is an essential source of information and analysis on the global rheumatoid arthritis (RA) market. The report identifies the key trends shaping and driving the global RA market. The report also provides insight into the prevalent competitive landscape and the emerging players likely to affect the market positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global RA sector.

For further details on this report, please or add the below link to your browser
http://www.global-market-research-data.com/CategorySearchResult.aspx?IndustryReport=rheumatoid_arthritis&CoreIndustry=All

Or visit our report store: http://www.globaldata.com/reportstore